Bilirubin blood test market seen reaching $2.08 billion by 2030

The bilirubin blood test market is projected to grow from $1.46 billion in 2025 to $2.08 billion by 2030, according to The Business Research Company. The report points to rising liver disease, neonatal screening, and wider use in primary care as the main drivers.

Why it matters: - The bilirubin blood test market is tied to liver health diagnostics, neonatal jaundice screening, and ongoing monitoring for liver disease. - Growth in testing demand reflects rising liver disease burdens and broader use of routine blood-based diagnostics in clinical care.

What happened: - The Business Research Company released a market report on the global bilirubin blood test market on July 29, 2026. - The report estimates the market will rise from $1.46 billion in 2025 to $1.57 billion in 2026. - The report projects the market will reach $2.08 billion by 2030. - The forecast implies a 7.3% compound annual growth rate from 2026 through 2030.

The details: - Bilirubin blood tests measure bilirubin levels in the bloodstream. - The test helps evaluate liver function and identify jaundice and other liver disorders. - The 2025-2026 growth is linked to neonatal jaundice screening programs, more hospital-based liver function tests, greater awareness of liver-related disorders, wider adoption of serum bilirubin testing, and growth in pediatric and infant diagnostics. - The longer-term outlook is driven by chronic liver disease, hepatitis, early liver health assessments, greater use in primary care, higher testing rates among aging and at-risk groups, and growth in point-of-care and specialized liver diagnostics. - The report highlights broader use of bilirubin testing for liver function evaluation, neonatal jaundice screening, hematology and pre-liver disease testing, and monitoring in hospital and clinical settings. - The report also points to a stronger focus on early detection and routine screening for liver health. - The report says North America held the largest market share in 2025. - The regional review also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Rising hospital admissions for liver disease in the UK underscore the kind of demand pressure supporting bilirubin testing. - GOV.UK data cited in the report showed UK hospital admissions for liver disease increased from 150.6 to 155.2 per 100,000 population between the fiscal years ending 2022 and 2023. - The market forecast suggests bilirubin testing is moving beyond specialized use and deeper into routine screening and primary care workflows.

What's next: - The market is likely to keep expanding as liver disease rates, neonatal screening, and point-of-care testing adoption increase. - The report expects continued demand from hospitals, clinics, and primary care settings through 2030. - The Business Research Company says future reports will add market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics, and updated trend graphics.